FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207588> ?p ?o ?g. }

• W4387207588 endingPage "S40" @default.
• W4387207588 startingPage "S39" @default.
• W4387207588 abstract "Prospective trials in early stage endometrial cancer demonstrate increased locoregional control with adjuvant radiotherapy for patients with high risk features. VCB is widely utilized, yet there is substantial practice variation and limited randomized data examining optimal dose/fractionation. We aimed to study the safety and efficacy of short course VCB compared to commonly used regimens.We conducted a prospective, randomized, multicenter trial examining short course adjuvant VCB (11 Gy x 2 fractions at the surface) compared with other standard regimens (7 Gy x 3 fractions at 0.5 cm depth, 6 Gy x 5 fractions at the surface, or 5-5.5 Gy x 4 fractions at 0.5 cm depth). Eligible patients underwent hysterectomy and had pathologically confirmed endometrioid adenocarcinoma, serous, clear cell, or carcinosarcoma. Patients with stage I and II cancers were included, with lymphovascular invasion (LVI) required for stage IAG1. The primary outcome was Global Health Status measured by the EORTC QLQ-C30 with a pre-specified non-inferiority margin of 15 points. Secondary outcomes included patient-reported outcomes, toxicities as assessed by CTCAEv5, and patterns of recurrence. Data were collected at each brachytherapy fraction and at 1-, 6-, and 12-month follow-up.One hundred eight patients were enrolled, 54 in each study arm. Data completion was 94%, 91%, and 77% at 1 month, 6 months, and 12 months, respectively. 70% of patients had endometrioid adenocarcinoma, 18% serous carcinoma, and 12% other histologies. 23% were FIGO grade 1, 33% grade 2, and 43% grade 3 or high risk histologies. The majority of patients were stage I (56% IA, 38% IB). 22% of patients had LVI. The QLQ-C30 Global Health Status for the experimental arm was within the predefined boundary and thus 2 fractions were non-inferior to standard of care at one month (p = 0.000005) and 12 months (p = 0.0005). Using EORTC EN24 for patient reported vaginal/sexual, urologic, and gastrointestinal symptoms, the change in mean patient reported symptom score from baseline to 1 month and baseline to 12 months were not significantly different between arms. Using CTCAEv5, 51 patients experienced short-term AEs related to study treatment, 20 in the experimental arm and 31 in the control arm (p = 0.053). All study treatment-related AEs were grade 1-2, except for two grade 3-4 AEs, both on the control arm. At median follow-up of 19 months, the isolated vaginal control rate in each arm was 100%. There was no significant difference in the total number of recurrences between study arms, with 3 distant and 3 distant/pelvic/vaginal recurrences in the experimental arm, and 2 distant, 2 pelvic, and 1 pelvic/vaginal recurrence in the control arm.Short course VCB is safe with acceptable acute toxicity and non-inferior patient reported outcomes. Short course VCB improves patient convenience and may improve access to care for rural or underserved populations while providing similar local control." @default.
• W4387207588 created "2023-09-30" @default.
• W4387207588 creator A5003680007 @default.
• W4387207588 creator A5011753105 @default.
• W4387207588 creator A5020238287 @default.
• W4387207588 creator A5021632957 @default.
• W4387207588 creator A5026710549 @default.
• W4387207588 creator A5030592365 @default.
• W4387207588 creator A5031484235 @default.
• W4387207588 creator A5034744116 @default.
• W4387207588 creator A5035912624 @default.
• W4387207588 creator A5041009445 @default.
• W4387207588 creator A5057224046 @default.
• W4387207588 creator A5073435015 @default.
• W4387207588 date "2023-10-01" @default.
• W4387207588 modified "2023-10-17" @default.
• W4387207588 title "Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer: Primary Endpoint Results of the SAVE Randomized Clinical Trial" @default.
• W4387207588 doi "https://doi.org/10.1016/j.ijrobp.2023.06.310" @default.
• W4387207588 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784490" @default.
• W4387207588 hasPublicationYear "2023" @default.
• W4387207588 type Work @default.
• W4387207588 citedByCount "0" @default.
• W4387207588 crossrefType "journal-article" @default.
• W4387207588 hasAuthorship W4387207588A5003680007 @default.
• W4387207588 hasAuthorship W4387207588A5011753105 @default.
• W4387207588 hasAuthorship W4387207588A5020238287 @default.
• W4387207588 hasAuthorship W4387207588A5021632957 @default.
• W4387207588 hasAuthorship W4387207588A5026710549 @default.
• W4387207588 hasAuthorship W4387207588A5030592365 @default.
• W4387207588 hasAuthorship W4387207588A5031484235 @default.
• W4387207588 hasAuthorship W4387207588A5034744116 @default.
• W4387207588 hasAuthorship W4387207588A5035912624 @default.
• W4387207588 hasAuthorship W4387207588A5041009445 @default.
• W4387207588 hasAuthorship W4387207588A5057224046 @default.
• W4387207588 hasAuthorship W4387207588A5073435015 @default.
• W4387207588 hasConcept C121608353 @default.
• W4387207588 hasConcept C126322002 @default.
• W4387207588 hasConcept C126894567 @default.
• W4387207588 hasConcept C141071460 @default.
• W4387207588 hasConcept C143998085 @default.
• W4387207588 hasConcept C168563851 @default.
• W4387207588 hasConcept C203092338 @default.
• W4387207588 hasConcept C2777088508 @default.
• W4387207588 hasConcept C2777416452 @default.
• W4387207588 hasConcept C2778740770 @default.
• W4387207588 hasConcept C2779013556 @default.
• W4387207588 hasConcept C2779494336 @default.
• W4387207588 hasConcept C509974204 @default.
• W4387207588 hasConcept C71924100 @default.
• W4387207588 hasConceptScore W4387207588C121608353 @default.
• W4387207588 hasConceptScore W4387207588C126322002 @default.
• W4387207588 hasConceptScore W4387207588C126894567 @default.
• W4387207588 hasConceptScore W4387207588C141071460 @default.
• W4387207588 hasConceptScore W4387207588C143998085 @default.
• W4387207588 hasConceptScore W4387207588C168563851 @default.
• W4387207588 hasConceptScore W4387207588C203092338 @default.
• W4387207588 hasConceptScore W4387207588C2777088508 @default.
• W4387207588 hasConceptScore W4387207588C2777416452 @default.
• W4387207588 hasConceptScore W4387207588C2778740770 @default.
• W4387207588 hasConceptScore W4387207588C2779013556 @default.
• W4387207588 hasConceptScore W4387207588C2779494336 @default.
• W4387207588 hasConceptScore W4387207588C509974204 @default.
• W4387207588 hasConceptScore W4387207588C71924100 @default.
• W4387207588 hasIssue "2" @default.
• W4387207588 hasLocation W43872075881 @default.
• W4387207588 hasLocation W43872075882 @default.
• W4387207588 hasOpenAccess W4387207588 @default.
• W4387207588 hasPrimaryLocation W43872075881 @default.
• W4387207588 hasRelatedWork W1995574347 @default.
• W4387207588 hasRelatedWork W2014411809 @default.
• W4387207588 hasRelatedWork W2109769594 @default.
• W4387207588 hasRelatedWork W2140632432 @default.
• W4387207588 hasRelatedWork W2326773849 @default.
• W4387207588 hasRelatedWork W2754341913 @default.
• W4387207588 hasRelatedWork W3194079830 @default.
• W4387207588 hasRelatedWork W3198485845 @default.
• W4387207588 hasRelatedWork W4205904040 @default.
• W4387207588 hasRelatedWork W4243611529 @default.
• W4387207588 hasVolume "117" @default.
• W4387207588 isParatext "false" @default.
• W4387207588 isRetracted "false" @default.
• W4387207588 workType "article" @default.